Plain-English translation of NCT06862856 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a new imaging scan called flotufolastat F 18 PET to find prostate cancer that may be coming back after surgery. The scan uses a radioactive agent that is already approved by the FDA. Researchers want to see how well this medication can detect cancer at very early stages when PSA levels are still very low.
After prostate cancer surgery, some men's cancer returns even when PSA levels are barely detectable. This medication may help doctors find where the cancer is coming back before it becomes more advanced, which could lead to better treatment options.
You likely qualify if…
You likely don't qualify if…
Your participation in this study is straightforward and relatively brief. After screening to confirm you are eligible, you will come for a second visit where you will receive an injection of the new imaging agent and then undergo a PET scan. The entire study participation is limited to the duration of this scan visit, making it a quick process with minimal time commitment.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Sponsor
Massachusetts General Hospital
Collaborators
Blue Earth Diagnostics
Enrollment target
~50 participants
Started
May 2025
Primary completion
January 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Sex
Male only
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jason Efstathiou, MD, DPhil
Massachusetts General Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.